Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
PEGylated drugs represent an innovative approach to delivering medicines, providing various advantages that enhance the effectiveness of treatments. This technology involves modifying molecules such as proteins, peptides, enzymes, antibody fragments, and oligonucleotides by attaching chains of ethylene glycol, a process known as PEGylation. This modification brings about benefits like reduced degradation by enzymes and minimized immune responses, ultimately improving the therapeutic efficacy of drugs.
The primary goal of PEGylation is to increase the bioavailability of drugs during the pharmacological process, ensuring that the drugs reach their intended targets more effectively. Consequently, PEGylated drugs tend to exhibit a significantly more efficient impact in treating various medical conditions.
The global PEGylated drugs market is anticipated to experience substantial growth due to several factors. The rise in chronic diseases, especially cancer, plays a significant role, with PEGylated drugs being increasingly recognized for their effectiveness in such conditions. The pharmaceutical industry's continuous expansion and advancements in the biologics sector also contribute to the positive outlook for the PEGylated drugs market. However, challenges exist, notably adverse reactions associated with PEGylated drugs and instances of drug recalls, which may hinder the market's growth during the assessment period.
Looking at the market forecast, it is estimated that the PEGylated Drugs Market will reach a value of USD 5900.55 Million by 2030, with a compound annual growth rate (CAGR) of 10% during the forecast period from 2022 to 2030.
The segmentation of the global PEGylated drugs market is based on the type of molecules and the medical indications they target. In terms of molecules, the protein segment holds the largest market share, accounting for 64.80% in 2018, with a market value of USD 6,017.50 million. This segment is projected to register a CAGR of 5.84% during the forecast period. On the other hand, when considering medical indications, the cancer segment dominates, constituting 62.46% of the market share in 2018, with a market value of USD 5,799.52 million. This segment is expected to witness a CAGR of 6.10% during the review period.
The dominance of the protein segment underscores the significance of PEGylated proteins in the pharmaceutical landscape. These modified proteins exhibit enhanced stability and extended circulation time in the body, making them valuable for various therapeutic applications.
In the realm of medical indications, the prominence of the cancer segment highlights the crucial role PEGylated drugs play in oncology. The unique properties conferred by PEGylation, such as prolonged circulation and reduced immunogenicity, make these drugs particularly effective in targeting and treating cancer cells.
While the market outlook is positive, it is essential to address challenges associated with adverse drug reactions and recalls. These issues emphasize the importance of rigorous testing and monitoring throughout the development and commercialization of PEGylated drugs to ensure patient safety and maintain the market's integrity.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|
PEGylated Drugs Market Highlights:
PEGylated Drugs Market Overview
The PEGylated Drugs Market is expected to reach USD 5900.55 Million by 2030 at %.10% CAGR during the forecast period 2022-2030.
Pegylated is the attachment process of covalent and non-covalent glycol polymer chains with bioactive molecules such as peptides, proteins, antibody fragments, enzymes and oligonucleotides etc. It is safe technique that is used in increasing the therapeutic efficiency of medicines in a clinical atmosphere. There are many fda approved pegylated drugs used for clinical purpose.
All the prominent key players are investing in R&D and Merger & Acquisitions. The key players have a plenty of molecules as their future projects.
The report comprises of detailed discussion on the benefit of the pegylated antibody, its market growth, driving factors and challenges. Also, it puts light on the major key players and their contribution and development in the PEGylated Proteins Market.
PEGylated Drugs Market dynamics
Drivers
The main driving force behind the growth of the PEGylated Drugs Market are, the rising of prevalence diseases such as cancer, advancement of biologics sectors, and increasing pharmaceutical industries all across the globe. Additionally, the increasing number of chronic ailments and death rates because of cancer in Canada will provide a boost to the growth of the pegylated drugs on market.
Challenges
Although the benefits of pegylated drugs are many, but there are some backdrops available as well with it. The side effects happening because of the drugs and the drug failure will make a restraining effect against the growth of the PEGylated Proteins Market during the forecast period.
Cumulative growth
PEGylated Drugs mainly have three benefits on the body.
- Pharmacokinetics and pharmacodynamic properties Improvement
According to studies, the pharmacokinetic properties drastically changes in the body along with prolonging the plasma half-life; it also increases the release of drugs in the body and reduces the renal clearance rate.
- Drug stability enhancement
A thicker hydration film forms on the surface preventing the precipitation and aggregation. The liposome stability is also increased by the modified linkage between lipid derivatives and PEG. Additionally, the flexible chain of PEG produces a hindrance effect which is steric protecting the modification from protease attack increasing the stability of the modification.
- Drug distribution improvement in the body
The molecular weight of the drugs increases in the body after being modified by PEG that help reducing the glomerular filtration effects during systemic administration. Therefore, it increases the excretion in the urination. Moreover, PEGylated drugs are also responsible for improving the stability in the systemic circulation and prolongs retention time which is highly beneficial in the distribution of the drugs in one's body. Particularly it helps in accumulating macromolecular drugs in inflammatory sites and tumours. Therefore, it increases the span of treatment of the drugs in vivo.
 PEGylated Drugs Market Revenue, by Molecule, 2018 (% share)  
Sources: MRFR Analysis
PEGylated Drugs Market Segmentation overview
Based on the PEGylated Drugs Market, it is segmented into-
- Molecule
- Indication
- Region
PEGylated Drugs Market, By Molecule
Based on molecule, the PEGylated Proteins Market is further segmented into-
- Protein
- FAB’ Fragment
- Enzyme
- Aptamer
PEGylated Drugs Market, By Indication Â
Based on indication, the PEGylated Proteins Market is further segmented into
- Cancer
- Gout
- Hemophilia
- Hepatitis
Cancer segment had 60% of the PEGylated Drugs Market share in 2017 owing to the increasing prevalence of diseases that demanded for a development in making effective drugs. The hepatitis segment is expected to grow at a CAGR of 12% over the forecast period. Moreover, the major key players focusing and developing the pegylated drugs using in chronic disease treatments will propel the growth of the market. For example, the market will be highly benefited with the launch of Pegasys drugs used for the treatment of Hepatitis C in adult patients.
 PEGylated Drugs Market Share, by Region, 2018 (%)    
Â
Sources: MRFR Analysis
PEGylated Drugs Market, by Region
Based on region, the PEGylated Drugs Market is further segmented into-
-
North America- US
- Canada
- Latin America
-
Europe- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
-
Asia-Pacific- China
- India
- Japan
- Australia & New Zealand
- Southeast Asia
- Rest of Asia-Pacific
-
Middle East & Africa- Middle East
- Africa
Â
PEGylated Drugs Market Regional analysis
Globally, the regional PEGylated Drugs Market is divided into Americas, Europe, Asia-Pacific and Middle East and Africa.
The American market is divided into North America and South America. The American market had a market share of 65.73% in 2018. U.S and Canada are the dominating region of the North American market. Canadian PEGylated Drugs Market is expected to witness a market growth of over 5.5% CAGR during the forecast period. The rising in the prevalence of chronic diseases such as cancer is driving the growth of the market. In 2017, more than 2lac people were diagnosed with cancer (as per the report of Canadian Cancer Society) which had emerged the demand of the pegylated drugs in the market.
Europe was the second-largest market in 2018. The European government supporting and investing in reducing chronic diseases is the driving force behind the growth the regional market. The European region is further classified into Western Europe and Eastern Europe. Western Europe is also classified into the UK, Italy, France, Spain and the rest of the Western Europe. Italian PEGylated Drugs Market had a revenue of USD 218 million in 2017 and expected to witness a growth at a CAGR of 9% during the forecast period.
The Asia-Pacific region is further clssified into India, China, Japan, Australia, South Korea and the rest of Asia-Pacific. APAC holds the third-largest position in the regional PEGylated Drugs Market.
The Middle East and Africa is anticipated to witness a significant growth due to the rising application of pegylated drugs for treating the chronic diseases.
Competitive landscape
Few industry key players operating the market growth are investing in R&D in PEGylated technology is providing a huge boost in the growth of the PEGylated Drugs Market. Â
Recent developments
In recent times, new  PEGylated drugs such as modified drugs using heterobifunctional PEG (X-PEG-Y) as a linker have been launched with the continuous deep research and developments. It is also believed that in future, the continuous modification in the technology will produce more and more effective and better drugs.
Major key players
There are several major key players in the market. The players operating in the PEGylated Drugs Market are focusing on developing and launching new products and expanding their footprints in the global and larger markets.Â
- Horizon Therapeutics Plc • F. Hoffmann-La Roche Ltd. • Pfizer Inc. • Novo Nordisk A/S • UCB S.A. • Amgen, Inc. • AstraZeneca. • Merck & Co., Inc. • Takeda Pharmaceutical Company Limited • Bayer AG • Biogen • BioMarin Pharmaceutical Inc • Coherus BioSciences • Enzon • Leadiant Biosciences, Inc.
Report Overview
The report comprises of
- Market overview
- Covid-19 impact
- Market dynamics
- Drivers
- Challenges
- Restrains
- Opportunities
- Technological analysis
- Segmentation overview
- Regional analysis
- Competitive landscape
- Recent developments
- Major key players
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
